Our Magazine
Brussels Morning Online Newspaper
Wednesday, April 14, 2021
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Online Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Online Newspaper
No Result
View All Result
Home Europe

UK first to approve BioNTech Pfizer vaccine

Sophia Akram by Sophia Akram
2 December 2020
in Europe
UK first to approve BioNTech Pfizer vaccine

A syringe and two bottles of COVID-19 vaccine on UK map. Covid vaccination in Great Britain. 3d illustration

Share on FacebookShare on Twitter

London (Brussels Morning) In a world-first, the UK has approved a vaccine developed by the German-American duo BioNTech and Pfizer. Rollout could commence as early as next week.

The race to develop a vaccine to immunise people against COVID-19 has ensued since the beginning of 2020 with around 200 candidates in progress. Several have reported high efficacy, including a drug developed by Moderna and Oxford University and AstraZeneca.

Ministers have called the prospect of the vaccine a “ray of hope” although administering it at a national level will remain challenging.

The Medicines and Healthcare products Regulatory Agency (MHRA), Britain’s regulatory authority on the use of new drugs, has stamped its approval on the vaccine just 23 days after final-stage clinical trial results were published.

UK Prime Minister Boris Johnson called the news “Fantastic”, but cautioned against over-excitement.

“At this stage it is very, very important that people do not get their hopes up too soon about the speed with which we will be able to roll out this vaccine”, he said.

Administration of the vaccine will take place in stages prioritising the most vulnerable as follows:

  • Care home residents and their carers.
  • Over 80s and frontline health and social care workers.
  • Over 75s.
  • Those 70 years and older and the clinically vulnerable.
  • Those 65s.
  • Anyone aged 16 to 64 with underlying health conditions with high risk of serious illness or mortality.
  • Over 60s.
  • Over 55s.
  • Over 50s.

The US and EU are also looking at the vaccine’s trial data but are yet to approve its use.

The EU regulator has defended its own longer procedures as more robust and appropriate.

Celebratory tones from among Britain’s political circles have also faced rebuke.

Germany’s ambassador to Britain Andreas Michaelis said, “I really don’t think this is a national story. In spite of the German company BioNTech having made a crucial contribution, this is European and transatlantic”.

MHRA has insisted, “No corners have been cut.

“Safety is our watchword”, said head of MHRA, June Raine.

The UK has ordered 40 million doses of the Pfizer vaccine to cover a third of the population. Those eligible to be first in line will likely be notified by letter.

Subscribe to Our Newsletter

Tags: BritanCoronavirus vaccineMain-Slider
Sophia Akram

Sophia Akram

Sophia Akram is the Brussels Morning London correspondent. Based in London, Sophia is a journalist with a portfolio rich in human rights, politics and foreign policy coverage, plus extensive experience in Europe, the Middle East and Asia.

Latest post

Now the Digital Markets Act is here, could this be what tames big tech?

Now the Digital Markets Act is here, could this be what tames big tech?

3 hours ago
Pandemic‌ ‌to‌ ‌set‌ ‌French‌ ‌finances‌ ‌back‌ ‌€424bn‌ ‌over‌ ‌three‌ ‌years‌ ‌

Pandemic‌ ‌to‌ ‌set‌ ‌French‌ ‌finances‌ ‌back‌ ‌€424bn‌ ‌over‌ ‌three‌ ‌years‌ ‌

8 hours ago

Most Read

  • A very Georgian provokatsiya

    A very Georgian provokatsiya

    0 shares
    Share 0 Tweet 0
  • The EU’s newest member state Croatia can teach the bloc much about building strategic autonomy

    0 shares
    Share 0 Tweet 0
  • EC to investigate €1bn worth of missing lumber in Croatian forests

    0 shares
    Share 0 Tweet 0
  • Salmond’s strategic masterstroke

    0 shares
    Share 0 Tweet 0
  • Vaccine export bans won’t help the fight against Covid-19, says Pfizer

    0 shares
    Share 0 Tweet 0

Subscribe
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • About Us
  • EU Institutions
    • Parliament
    • Commission
    • Council
  • Europe
  • World
  • Member States
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • The American Angle
    • Southeast Europe
  • Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT